Impact of cardiovascular burden on coagulation pathway in apparently healthy women planning oocyte donation

• Published in: Clinical hemorheology and microcirculation Vol. 79; no. 4; pp. 531 - 539
• Main Authors: Cirillo, Michela, Attanasio, Monica, Paniccia, Rita, Rizzello, Francesca, Coccia, Maria Elisabetta, Fatini, Cinzia
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2021
• Subjects: Blood Coagulation; Blood Coagulation Tests; Female; Humans; Infertility, Female; Oocyte Donation; Thrombelastography; women’s health; hemostasis; Oocyte donation; blood coagulation tests; assisted reproductive techniques
• ISSN: 1386-0291; 1875-8622
• DOI: 10.3233/CH-211108

BACKGROUND: Hormonal fertility treatments are associated with increased coagulation factors inducing procoagulant milieu and possibly thrombotic risk. OBJECTIVE: To assess coagulation by ROTEM and coagulation tests in apparently healthy infertile women before oocyte donation procedure. METHODS: We enrolled 51 women (Assisted Reproductive Technology Centre, Florence). ROTEM and coagulation parameters were assessed before the start of infertility treatment. RESULTS: We divided women in 3 groups according to the number of cardiovascular risk factors: Group A (n = 10), Group B (n = 16), and Group C (n = 25). By considering ROTEM Extem test, a significantly increased of MCF, TPI, and G were observed in groups B (p = 0.005, p = 0.03, and p = 0.007) and C (p = 0.01, p = 0.05, and p = 0.005) in comparison to group A. As regards ROTEM Intem test, the TPI and G values were significantly higher in groups B and C in comparison to group A (p < 0.01). MCF by Fibtem test significantly increased in groups B and C than in group A (p = 0.004 and p = 0.002, respectively). FVIII, vWF:Ag and D-dimer values significantly increase according to the presence of≥2 risk factors. CONCLUSIONS: Data from coagulative assessment permit to sensitively identify women with potentially procoagulable state, which represents a risk factor of thromboembolic event during hormone treatment.